Thursday, September 5, 2013
Publication and contact
Small molecules that
prevent teratoma formation in human pluripotent stem cell-derived therapies
Small molecules that are
selectively toxic to human pluripotent stem cells could help decrease the
tumorigenicity risk of stem cell-derived therapies. Residual,
undifferentiated stem cells in stem cell-derived cell therapies can lead to
teratoma formation. In mixed cultures of differentiated human cells and
undifferentiated human stem cells, small molecule inhibitors of survivin
such as sepantronium,
and small molecule inhibitors of B cell CLL lymphoma 10 (BCL10)
selectively induced apoptosis in undifferentiated cells. In a mixture of
differentiated human cells and undifferentiated human stem cells injected
into mice, none of the cell mixtures pretreated with sepantronium or another
small molecule survivin inhibitor developed teratomas, whereas all the
untreated cell mixtures did. Next steps include developing more specific
inhibitors of survivin and BCL10.
Pharma Inc.'s sepantronium, a survivin expression
inhibitor, is in Phase II testing to treat non-Hodgkin's lymphoma (NHL).
Pharmaceutical LLC's Terameprocol
nordihydroguaiaretic acid, a small molecule inhibitor of the
production and activation of survivin, is in Phase I for multiple cancers.
Published online Sept. 5, 2013
Patent application filed;
unavailable for licensing
Lee, M-.O. et al. Proc.
Natl. Acad. Sci. USA; published online Aug. 5, 2013;
Contact: Hyuk-Jin Cha, Sogang University, Seoul, South Korea
Contact: Kwang-Soo Kim, Harvard Medical School, Boston,
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]